FierceBiotech Names Pandion Therapeutics as One of Its “Fierce 15” Biotech Companies of 2018

October 2, 2018

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct 2, 2018--Pandion Therapeutics today announced that it has been named by FierceBiotech as one of 2018’s Fierce 15 biotechnology companies, designating it as one of the most promising private biotechnology companies in the industry.

Pandion is developing a new class of drugs to treat diseases with high unmet medical need, including inflammatory bowel disease, autoimmune liver disease, kidney diseases, type 1 diabetes, and autoimmune skin conditions. Pandion’s approach is shifting the paradigm from systemic immunosuppression to therapies that act locally at the site of disease to restore immune homeostasis.

“We are delighted to be recognized by FierceBiotech as one of their Fierce 15,” said Dr Anthony Coyle, CEO and President of Pandion. “We are building an exciting, energetic and bold company with a dynamic and diverse team, and we are privileged to be making new drugs that we believe will meaningfully impact the lives of many patients.”

The Fierce 15 celebrates the spirit of being “fierce”—championing innovation and creativity, even in the face of intense competition. This is FierceBiotech’s 16 th annual Fierce 15 selection.

An internationally recognized daily report reaching a network of over 285,000 biotech and pharma industry professionals, FierceBiotech provides subscribers with an authoritative analysis of the day’s top stories. Every year FierceBiotech evaluates hundreds of private companies from around the world for its annual Fierce 15 list, which is based on a variety of factors such as the strength of its technology, partnerships, venture backers and a competitive market position.

About Pandion Therapeutics Pandion Therapeutics  is a biotechnology company developing a pipeline of antibody therapeutics to achieve localized immunomodulation for autoimmune and inflammatory diseases and transplantation. The company’s proprietary technology platform enables the design of bispecific antibodies with targeting fragments that bind to specific tissues at the local site of inflammatory disease, coupled with effector molecules that modulate immune activity to restore immune homeostasis.

Pandion was founded in 2017 and closed a $58M Series A financing round in early 2018 with funding from Polaris Partners, Versant Ventures, Roche Venture Fund, SR One and BioInnovation Capital. The company is headquartered in Cambridge, Massachusetts. Please visit  www.pandiontx.com.

About FierceBiotech FierceBiotech is the biotech industry’s daily monitor, an email newsletter and web resource providing the latest biotech news, articles, and resources related to clinical trials, drug discovery, FDA approval, FDA regulation, patent news, pharma news, biotech company news and more. More than 150,000 top biotech professionals rely on FierceBiotech for an insider briefing on the day’s top stories. Signup is free at www.fiercebiotech.com/signup.

View source version on businesswire.com:https://www.businesswire.com/news/home/20181002005477/en/

CONTACT: Pandion Therapeutics

Anthony Coyle




Rebecca Willumson, 202-824-5050




SOURCE: Pandion Therapeutics

Copyright Business Wire 2018.

PUB: 10/02/2018 09:00 AM/DISC: 10/02/2018 09:01 AM


Update hourly